Humoral immunodeficiency disrupts bile-acid-induced immune tolerance in the small intestine
体液免疫缺陷破坏胆汁酸诱导的小肠免疫耐受
基本信息
- 批准号:10664252
- 负责人:
- 金额:$ 24.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAdoptive TransferAmino AcidsAntibodiesAntibody ResponseB-LymphocytesBacteriaBile AcidsBile Acids and SaltsBindingBiochemistryCD19 geneCeliac DiseaseCell MaturationCellsChronicChronic DiseaseChronic diarrheaClinicalColonCommon Variable ImmunodeficiencyComplicationCrohn&aposs diseaseDefectDevelopmentDiagnosisDiarrheaDietary FatsDiseaseEnzymesFlow CytometryHeritabilityHomeostasisHumanHumoral ImmunitiesHydrolaseIgA DeficiencyImmuneImmune ToleranceImmune responseImmunoglobulin AImmunoglobulin MImmunologic Deficiency SyndromesInflammatoryIntestinal ContentIntravenous ImmunoglobulinsLeadLinkLipidsLiverMalabsorption SyndromesMetabolicMetabolic BiotransformationMetabolic DiseasesMetabolismModelingMucous MembraneOralPatientsPerformancePharmacologyPhenotypePlayPopulationProductionPublishingReactionRecurrenceRefractoryResearchRisk FactorsRoleSerumSignaling MoleculeSmall IntestinesSupplementationTechniquesTestingTherapeutic InterventionTissuesTreatment EfficacyTropical sprueVitaminsWorkabsorptionbile acid metabolismbile saltsclinically relevantcommensal bacteriacongenital immunodeficiencydysbiosisefficacy testingexperimental studygastrointestinalgastrointestinal symptomhuman diseaseimmunoregulationinnovationintestinal homeostasisknock-downliquid chromatography mass spectrometrymetatranscriptomicsmicrobial colonizationmicrobial communitymicrobiomemicrobiome compositionmicrobiotamouse modelnext generation sequencingnoveloral supplementationprogramsresponsesingle-cell RNA sequencingtauroursodeoxycholic acid
项目摘要
Project Summary
Humoral immunodeficiency is the most frequently diagnosed form of primary immunodeficiency in humans.
Common variable immunodeficiency (CVID) is the most clinically severe form, and chronic gastrointestinal
complications are both common in CVID patients and refractory to treatment by intravenous Ig therapy. A severe
GI disorder is termed 'CVID enteropathy'; a small intestine (SI)-specific enteropathy that presents clinically as
chronic diarrhea and malabsorption. Bile acids (BAs) are emulsifiers produced by the liver and secreted into the
gut that promote the solubilization and absorption of dietary lipids and lipid-soluble vitamins. They may also serve
as signaling molecules capable of inducing tolerogenic responses in tissue-resident immune cells. Mucosal
antibody deficiency alters microbiota composition. Given that the microbiota profoundly influence luminal BA
biochemistry, the overarching hypothesis this R01 proposal will address is that mucosal antibody-
deficiency results in aberrant bacterial BA metabolism that abolishes BA-induced immunological
tolerance in the SI. In this proposal, we provide evidence supporting that mucosal antibody-deficiency results
in aberrant inflammatory immune responses that are associated with the development of SI enteropathy;
potentially driven by elevated bacterial bile salt hydrolase (bsh) activity that causes BA malabsorption (BAM).
We also identify that bsh ablation or oral BA supplementation alleviates BAM and suppresses inflammatory
disease. The objective of Specific Aim #1 is to define how humoral immunity influences BA homeostasis, and
how this coordinates establishment of a tolerogenic immune phenotype in the SI. Several complementary models
will be utilized to address this fundamental question and will incorporate the advanced techniques of ultra-purity
liquid chromatography mass spectrometry (UPLC-MS) to comprehensively characterize BA pool composition,
and paired high-parameter flow cytometry and single cell RNA sequencing to characterize SI-resident immune
cell phenotypes. The objective of Specific Aim #2 is to demonstrate how mucosal antibody deficiency influences
the composition and BA-metabolizing capacity of the SI-resident microbial community. Several novel and
complementary microbial colonization models, adoptive transfer models, and next-gen sequencing approaches
will be utilized to address this. The objective of Specific Aim #3 is to test the efficacy of two candidate approaches
to alleviate inflammatory SI enteropathies and involve oral BA supplementation or pharmacological knockdown
of bacterial bsh activity. Innovations from this research include the first analysis of the role of humoral immunity
plays in regulating BA metabolism, a comprehensive assessment of the role mucosal IgA and IgM antibody
responses play in SI homeostasis, characterization of a novel mechanism by which dysbiosis drives disease,
and characterization of the role bsh ablation and oral BA supplementation play in tolerogenic re-programming of
SI-resident immune cells in the setting of chronic disease. Beyond, CVID, results of this work are relevant to
other SI enteropathies in humans including Crohn's disease, celiac disease, and tropical sprue.
项目摘要
体液免疫缺陷是人类原发性免疫缺陷最常见的诊断形式。
常见变异型免疫缺陷(CVID)是临床上最严重的形式,慢性胃肠道免疫缺陷(CVID)是一种常见的免疫缺陷。
并发症在CVID患者中是常见的,并且对静脉内IG疗法的治疗是难治的。严重
胃肠道疾病被称为“CVID肠病”;一种小肠(SI)特异性肠病,临床表现为
慢性腹泻和吸收不良。胆汁酸(BA)是由肝脏产生并分泌到肝脏中的乳化剂。
促进膳食脂质和脂溶性维生素溶解和吸收的肠道。他们也可以服务于
作为能够在组织驻留免疫细胞中诱导致耐受性应答的信号分子。粘膜
抗体缺乏会改变微生物群的组成。鉴于微生物群深刻地影响了管腔BA
生物化学,总体假设,这R 01建议将解决的是,粘膜抗体-
缺乏导致异常的细菌BA代谢,其破坏BA诱导的免疫应答。
对SI的宽容。在这个建议中,我们提供的证据支持粘膜抗体缺乏的结果,
在与SI肠病的发展相关的异常炎性免疫应答中;
可能由引起BA吸收不良(BAM)的细菌胆盐水解酶(bsh)活性升高驱动。
我们还发现,bsh消融或口服BA补充剂可加重BAM并抑制炎症反应。
疾病具体目标#1的目的是确定体液免疫如何影响BA稳态,
这如何协调SI中致耐受性免疫表型的建立。几种互补模式
将用于解决这一基本问题,并将采用先进的超纯技术,
液相色谱质谱法(UPLC-MS)以全面表征BA合并液组成,
并配对高参数流式细胞术和单细胞RNA测序来表征SI驻留免疫
细胞表型具体目标#2的目的是证明粘膜抗体缺乏如何影响
SI驻留微生物群落的组成和BA代谢能力。一些小说和
互补的微生物定植模型、过继转移模型和下一代测序方法
将被用来解决这个问题。具体目标#3的目的是测试两种候选方法的有效性
减轻炎性SI肠病,并涉及口服BA补充或药物敲低
细菌的BSH活性。这项研究的创新包括首次分析了体液免疫的作用
发挥调节BA代谢、综合评价粘膜伊加和IgM抗体的作用
反应在SI稳态中起作用,表征了生态失调驱动疾病的新机制,
和表征bsh消融和口服BA补充在耐受性重编程中的作用。
慢性疾病背景下的SI驻留免疫细胞。除此之外,CVID,这项工作的结果与
人类的其他SI肠病,包括克罗恩病、乳糜泻和热带口炎性腹泻。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason L Kubinak其他文献
Jason L Kubinak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason L Kubinak', 18)}}的其他基金
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut Microbiota
B 细胞固有的 MHCII 信号传导是 IgA 库和肠道微生物群选择的多样化力量
- 批准号:
10409841 - 财政年份:2021
- 资助金额:
$ 24.65万 - 项目类别:
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut Microbiota
B 细胞固有的 MHCII 信号传导是 IgA 库和肠道微生物群选择的多样化力量
- 批准号:
10299067 - 财政年份:2021
- 资助金额:
$ 24.65万 - 项目类别:
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut Microbiota
B 细胞固有的 MHCII 信号传导是 IgA 库和肠道微生物群选择的多样化力量
- 批准号:
10614060 - 财政年份:2021
- 资助金额:
$ 24.65万 - 项目类别:
Altered Bacterial Bile Acid Metabolism as a Driver of CVID Enteropathy
细菌胆汁酸代谢的改变是 CVID 肠病的驱动因素
- 批准号:
10220550 - 财政年份:2020
- 资助金额:
$ 24.65万 - 项目类别:
Exploring how B cell Maturation Pathways Influence Microbiota Composition and Host Health
探索 B 细胞成熟途径如何影响微生物群组成和宿主健康
- 批准号:
9089576 - 财政年份:2017
- 资助金额:
$ 24.65万 - 项目类别:
Altered Bacterial Bile Acid Metabolism as a Driver of CVID Enteropathy
细菌胆汁酸代谢的改变是 CVID 肠病的驱动因素
- 批准号:
10227914 - 财政年份:2012
- 资助金额:
$ 24.65万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24.65万 - 项目类别:
Research Grant














{{item.name}}会员




